0A4Y Stock Chart & Stats
$0.26
>-$0.01(-2.01%)
At close: 4:00 PM EDT
$0.26
>-$0.01(-2.01%)
Day’s Range― - ―
52-Week Range$0.20 - $3.32
Previous CloseN/A
Volume2.60K
Average Volume (3M)191.48K
Market Cap
$8.07M
Enterprise Value-$1.18
Total Cash (Recent Filing)$9.96M
Total Debt (Recent Filing)$3.92M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.84
Shares Outstanding37,429,420
10 Day Avg. Volume52,690
30 Day Avg. Volume191,481
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.25Price Target Upside1534.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$61.00K
Bulls Say, Bears Say
Bulls Say
Modest Current LeverageA relatively small debt balance reduces immediate interest and repayment pressure compared with a heavily leveraged structure. This gives AIM more flexibility to direct scarce resources toward clinical development, although continued losses mean the balance sheet still requires careful management.
Listing Compliance RestoredRestoring exchange compliance removes an important operational constraint and supports access to public-market financing and investor visibility. The capital raised also provides resources for ongoing operations and development, strengthening near-term continuity even though the financing involved equity issuance.
Ampligen Manufacturing ReadinessExpanding manufacturing capacity and transferring test methods can improve readiness for ongoing and future clinical studies, including a potential Phase 3 pancreatic-cancer trial. This supports advancement of the lead program by addressing supply needs as development activity grows.
Bears Say
Minimal Commercial RevenueThe very small revenue base and deeply negative gross profit show that AIM has not yet established meaningful commercial economics. Persistent operating and net losses make future performance dependent on successful clinical progress, regulatory outcomes, and eventual product commercialization.
Persistent Cash BurnSustained negative operating and free cash flow means the company is consuming cash to fund its activities rather than financing them internally. This weak cash-generation profile can constrain development choices and increase the need for recurring external capital over the coming quarters.
Equity-Financed Debt ReductionConverting debt into a large number of common shares reduces obligations but increases the share count and dilutes existing ownership. Repeated reliance on equity exchanges to manage liabilities signals that balance-sheet improvement is being achieved partly at shareholders’ expense.
AIM ImmunoTech News
0A4Y FAQ
What was AIM ImmunoTech’s price range in the past 12 months?
AIM ImmunoTech lowest share price was $0.20 and its highest was $3.32 in the past 12 months.
What is AIM ImmunoTech’s market cap?
AIM ImmunoTech’s market cap is $8.07M.
When is AIM ImmunoTech’s upcoming earnings report date?
AIM ImmunoTech’s upcoming earnings report date is Aug 17, 2027 which is in 326 days.
How were AIM ImmunoTech’s earnings last quarter?
AIM ImmunoTech released its earnings results on Aug 10, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.26.
Is AIM ImmunoTech overvalued?
According to Wall Street analysts AIM ImmunoTech’s price is currently Undervalued.
Does AIM ImmunoTech pay dividends?
AIM ImmunoTech does not currently pay dividends.
What is AIM ImmunoTech’s EPS estimate?
AIM ImmunoTech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AIM ImmunoTech have?
AIM ImmunoTech has 37,429,420 shares outstanding.
What happened to AIM ImmunoTech’s price movement after its last earnings report?
AIM ImmunoTech reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -6.429%.
Which hedge fund is a major shareholder of AIM ImmunoTech?
Currently, no hedge funds are holding shares in GB:0A4Y
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
0A4Y Stock 12 Month Forecast
Average Price Target
$4.25
▲(1534.62% Upside)